ipilimumab,nivolumab
bms
['nsclc', 'nivo', 'sclc', 'diciple', 'ipilimumab', 'nivolumab']
the #oncoalerttoptweet #esmo22 day 3 tweet diciple compare short vs extended immuno tx 6-months nivolumab + ipilimumab continuation in patients with nsclc (ifct-1701) unfortunately halted, but important signal: not detrimental&amp; safer! best, 
?? Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees ?? We are #OncoAlert ??